(2016). The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis. IMA PRESS LLC.
Chicago Style (17th ed.) CitationThe Expert Meeting Dedicated to the Discussion of Results of a Local Open-label Multicenter Observational Study of the Efficiency and Safety of Tofacitinib in Patients with Active Rheumatoid Arthritis with the Inefficiency of Disease-modifying Antirheumatic Drugs and to the Elaboration of Recommendations for the Use for Tofacitinib in the Therapy of Rheumatoid Arthritis. IMA PRESS LLC, 2016.
MLA (9th ed.) CitationThe Expert Meeting Dedicated to the Discussion of Results of a Local Open-label Multicenter Observational Study of the Efficiency and Safety of Tofacitinib in Patients with Active Rheumatoid Arthritis with the Inefficiency of Disease-modifying Antirheumatic Drugs and to the Elaboration of Recommendations for the Use for Tofacitinib in the Therapy of Rheumatoid Arthritis. IMA PRESS LLC, 2016.